Anand A. Dalal

Novartis (United States) — United States

Medicine · Health Sciences

33h-index3.7kcitations130works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Obstructive Pulmonary Disease (COPD) Research(68), Asthma and respiratory diseases(33), Respiratory Support and Mechanisms(22), Respiratory and Cough-Related Research(20), Advanced Breast Cancer Therapies(14)

Publications130 total

Multi-Stakeholder Qualitative Interviews to Inform Measurement of Patient Reported Outcomes After CAR-T
Transplantation and Cellular Therapy·2023· 20 citedOpen Access
Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy – a retrospective cohort study using CMS 100% Medicare claims database
Leukemia & lymphoma/Leukemia and lymphoma·2022· 8 citedOpen Access
Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States
Leukemia & lymphoma/Leukemia and lymphoma·2022· 12 citedOpen Access
Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ)
UNC Libraries·2021Open Access
Economic burden prior to COPD diagnosis: A matched case-control study in the United States
UNC Libraries·2021· 11 citedOpen Access
Table of Contents
Clinical Therapeutics·2021Open Access
Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States
Clinical Therapeutics·2021· 30 cited
Healthcare resource use (HRU) by infusion setting of chimeric antigen receptor T-cell (CAR-T) in patients with relapsed and refractory (r/r) diffuse large B-cell lymphoma (DLBCL): A retrospective cohort study using CMS 100% Medicare database.
Journal of Clinical Oncology·2021· 3 cited
Estimating costs of adverse events (AEs) and healthcare resource use (HRU) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) receiving tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel): A summary of real-world evidence.
Journal of Clinical Oncology·2021
Prevalence of Airway Obstruction Assessed by Lung Function Questionnaire
UNC Libraries·2020Open Access
Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims
Dove Medical Press (Taylor and Francis Group)·2020Open Access
Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer
Journal of Managed Care & Specialty Pharmacy·2019· 12 citedOpen Access
Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2− breast cancer
The Breast Journal·2019· 5 citedOpen Access
Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic Model
JCO Precision Oncology·2019· 220 cited
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study
Clinical Breast Cancer·2019· 16 cited
Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer
Lung Cancer·2018· 19 cited
Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2− Advanced Breast Cancer
Advances in Therapy·2018· 12 cited
Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2− advanced or metastatic breast cancer
Current Medical Research and Opinion·2018· 8 cited
COPD affects worker productivity and health care costs
International Journal of COPD·2018· 57 citedOpen Access
Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2− Metastatic Breast Cancer
Advances in Therapy·2018· 1 cited
page 1 of 7Next →

Frequent Co-authors

Douglas W. Mapel(10), Christopher M. Blanchette(8), Manan Shah(6), Anna O. D’Souza(6), Richard H. Stanford(6), Alex Mutebi(4), Frank C. Albers(4), Steve Yancey(4), Héctor Ortega(4), Mark Forshag(4), Saurabh Nagar(4), Jeetvan Patel(4), Matthew L. Mintz(4), Nicola A. Hanania(4), Patrick Lefèbvre(3), Mei Sheng Duh(3), Laurence Gozalo(3), Marie-Noëlle Robitaille(3), Xiwu Lin(3), Manabu Akazawa(3)